Your browser is no longer supported. Please, upgrade your browser.
XERS Xeris Pharmaceuticals, Inc. daily Stock Chart
Xeris Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.41 Insider Own2.90% Shs Outstand19.75M Perf Week-34.70%
Market Cap192.17M Forward P/E- EPS next Y-3.18 Insider Trans- Shs Float19.10M Perf Month-43.33%
Income-48.80M PEG- EPS next Q-0.94 Inst Own64.50% Short Float3.71% Perf Quarter-52.61%
Sales2.10M P/S91.51 EPS this Y-101.00% Inst Trans28.79% Short Ratio6.74 Perf Half Y-59.88%
Book/sh4.58 P/B2.12 EPS next Y43.00% ROA- Target Price26.00 Perf Year-
Cash/sh6.63 P/C1.47 EPS next 5Y- ROE- 52W Range9.21 - 27.98 Perf YTD-42.76%
Dividend- P/FCF- EPS past 5Y- ROI46.00% 52W High-65.23% Beta-
Dividend %- Quick Ratio16.50 Sales past 5Y- Gross Margin98.00% 52W Low5.65% ATR0.96
Employees70 Current Ratio16.50 Sales Q/Q200.00% Oper. Margin- RSI (14)20.65 Volatility8.34% 5.84%
OptionableNo Debt/Eq0.33 EPS Q/Q-86.50% Profit Margin- Rel Volume4.47 Prev Close9.21
ShortableYes LT Debt/Eq0.33 EarningsFeb 13 Payout- Avg Volume105.33K Price9.73
Recom- SMA20-32.70% SMA50-42.06% SMA200-50.92% Volume470,344 Change5.65%
Jul-16-18Initiated RBC Capital Mkts Outperform $24
Jul-16-18Initiated Leerink Partners Outperform $24
Jul-16-18Initiated Jefferies Buy $23
Feb-13-19 07:26PM  Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock GlobeNewswire -8.67%
Feb-12-19 04:33PM  Why Molson Coors Brewing, Xeris Pharmaceuticals, and Varonis Systems Slumped Today Motley Fool -21.50%
08:04AM  The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares Benzinga
Feb-11-19 04:05PM  Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock GlobeNewswire
Dec-20-18 08:30AM  European Medicines Agency Grants Orphan Drug Designation for Xeris Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS) Business Wire -11.96%
Nov-07-18 08:00AM  Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress GlobeNewswire
Oct-23-18 08:30AM  Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen Business Wire
Aug-17-18 08:30AM  Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris Novel Ready-to-Use Liquid Glucagon Business Wire
Aug-13-18 08:00AM  Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights GlobeNewswire
Jul-31-18 07:00AM  Xeris Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire
Jul-30-18 07:00AM  Xeris Pharmaceuticals Announces New Board Members and New Executive to Management Team GlobeNewswire
Jun-26-18 04:15PM  Xeris Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jun-25-18 04:15PM  Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen Business Wire
Jun-21-18 11:41AM  [$$] Banner Day for Biotech as Five Drug Developers Go Public The Wall Street Journal
Jun-20-18 06:31PM  Xeris Pharmaceuticals Announces Pricing of Initial Public Offering of Common Stock GlobeNewswire
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company's preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.